AGRA Before and After Liver Transplantation

StatusActive, Not Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Dec 2026 to Dec 2027
    • Eligibility criteria expanded, about 5 words
  2. Study completion date: Dec 2024 to Dec 2026v11
  3. Re-verified, no change to tracked fieldsv10
  4. Primary completion date: Dec 31, 2021 to May 31, 2023
    • Study completion date: Jul 2023 to Dec 2024
    v9
  5. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 108 to confirmed 76
    • Study completion date: Jul 2022 to Jul 2023
    • Site details revised
    v8
Show 6 earlier versionsHide 6 earlier versions
  1. Primary completion date changed from estimate of Dec 2021 to Dec 31, 2021v7
  2. Primary completion date: Jul 2021 to Dec 2021v6
  3. Re-verified, no change to tracked fieldsv5
  4. Primary completion date: Jul 2019 to Jul 2021
    • Study completion date: Jul 2020 to Jul 2022
    v4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 2018 to Jul 6, 2018
    v3
  6. Start date: Apr 2018 to Jul 2018
    • Primary completion date: Apr 2019 to Jul 2019
    • Study completion date: Apr 2020 to Jul 2020
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The immune system is impaired in liver cirrhotic patients, which is associated with a high risk for bacterial infections and worse outcome. A novel biomarker, acellular growth retardation ability (AGRA), can predict the development of severe infections in patients with liver cirrhosis and therefore identify patients at risk. It is still unclear, how this biomarker develops after liver transplantation and how valid its predictions are for post-operative infections. Therefore, AGRA will be measured before and after liver transplantation and predictive merit of AGRA for post-transplant infections will be tested.
Trial Details
NCT Number NCT03446521
Lead Sponsor Medical University of Graz
Conditions
(from sponsor)		 Liver Cirrhosis
Related terms Liver Cirrhosis
Enrollment 76 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov